Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod
The FDA has approved Heron Therapeutics Inc’s HRTX supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures, including foot and ankle, and other procedures in which direct…#fda #zynrelef #heron #crosslink #vialaccessneedle #craigcollard #nda #hrtx (Source: Reuters: Health)
Source: Reuters: Health - January 24, 2024 Category: Consumer Health News Source Type: news
Heron Therapeutics Announces Approval of ZYNRELEF(R) by Health Canada for the Management of Postoperative Pain
ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada
SAN DIEGO, March 17, 2022 -- (Healthcare Sales & Marketing Network) -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused ... Biopharmaceuticals, Drug Delivery, Regulatory Heron Therapeutics, ZYNRELEF, bupivacaine, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2022 Category: Pharmaceuticals Source Type: news
Meloxicam Tablets (meloxicam ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 4, 2021 Category: Drugs & Pharmacology Source Type: news
Zynrelef (Bupivacaine and Meloxicam) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 22, 2021 Category: Drugs & Pharmacology Source Type: news
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
ZYNRELEF, the first and only extended-release local anesthetic, is now available in distribution channels
Heron has deployed new acute care sales representatives across the U.S.
SAN DIEGO, July 1, 2021 -- (Healthcare Sales & Marketing Network) -- He... Biopharmaceuticals, Drug Delivery, Product Launch Heron Therapeutics, ZYNRELEF, bupivacaine, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 1, 2021 Category: Pharmaceuticals Source Type: news
Zynrelef (Bupivacaine and Meloxicam) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 20, 2021 Category: Drugs & Pharmacology Source Type: news
Qmiiz-ODT (Meloxicam Orally Disintegrating Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 14, 2021 Category: Drugs & Pharmacology Source Type: news
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to eliminate the need for opioids for up to 72 hours following surgery better than bupivacaine solution, the current standard-of... Biopharmaceuticals, FDA Heron Therapeutics, ZYNRELEF, bupivacaine, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain
SAN DIEGO, May 13, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 13, 2021 Category: Drugs & Pharmacology Source Type: news
Anjeso (meloxicam)
Title: Anjeso (meloxicam)Category: MedicationsCreated: 5/7/2021 12:00:00 AMLast Editorial Review: 5/7/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 7, 2021 Category: Drugs & Pharmacology Source Type: news
Vivlodex (meloxicam)
Title: Vivlodex (meloxicam)Category: MedicationsCreated: 5/7/2021 12:00:00 AMLast Editorial Review: 5/7/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 7, 2021 Category: Rheumatology Source Type: news
Efficacy of Non-opioid Analgesics to Control Postop Pain Efficacy of Non-opioid Analgesics to Control Postop Pain
This meta-analysis investigated the efficacy of intravenous meloxicam, as well as other IV non-opioid analgesics, for moderate to severe acute postoperative pain.BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 24, 2020 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain
The CHMPS has recommended granting marketing authorization for the nonopioid drug to treat surgical pain, as well as for a generic form of Fampyra to treat multiple sclerosis associated with walking disability.International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 24, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
NSAID/Triptan Combo Improves Treatment-Resistant Migraine NSAID/Triptan Combo Improves Treatment-Resistant Migraine
A combination of rizatriptan and the NSAID meloxicam formulated to improve oral absorption led to better pain control than did rizatriptan alone in a phase 3 clinical trial.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 19, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
MOMENTUM: Combination Product Shows Promise in Migraine MOMENTUM: Combination Product Shows Promise in Migraine
A new product combining rizatriptan and a proprietary formulation of meloxicam has shown encouraging results in migraine patients with unmet medical need, in a phase 3 trial.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 2, 2020 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
